M S Patnaik

List of Publications by Year in descending order

482 papers	10,348 citations	31976 53 h-index	54911 84 g-index
488 all docs	488 docs citations	488 times ranked	9902 citing authors

#	Article	IF	Citations
1	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood, 2009, 113, 5727-5736.	1.4	484
2	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 2019, 133, 697-709.	1.4	408
3	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. New England Journal of Medicine, 2015, 373, 908-919.	27.0	276
4	Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia, 2009, 23, 1343-1345.	7.2	255
5	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia, 2014, 28, 2206-2212.	7.2	237
6	SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 2012, 119, 569-572.	1.4	203
7	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia, 2013, 27, 1504-1510.	7.2	190
8	Myelodysplastic syndromes: Contemporary review and how we treat. American Journal of Hematology, 2016, 91, 76-89.	4.1	153
9	Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. American Journal of Hematology, 2013, 88, 201-206.	4.1	134
10	FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia Research, 2006, 30, 965-970.	0.8	131
11	Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia, 2012, 26, 101-105.	7.2	129
12	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M</scp>ayo <scp>C</scp>linicâ€<scp>F</scp>rench <scp>C</scp>onsortium <scp>S</scp>tudy. American Journal of Hematology, 2014, 89, 1111-1115.	4.1	129
13	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal, 2015, 5, e333-e333.	6.2	117
14	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	3.5	105
15	Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 97-115.	4.1	105
16	The Incidence and Severity of Oral Mucositis among AllogeneicÂHematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 605-616.	2.0	103
17	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	3.0	103
18	The complete evaluation of erythrocytosis: congenital and acquired. Leukemia, 2009, 23, 834-844.	7.2	102

#	Article	IF	Citations
19	Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer Journal, 2016, 6, e393-e393.	6.2	102
20	The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	101
21	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	7.2	101
22	Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. American Journal of Hematology, 2018, 93, 824-840.	4.1	101
23	Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood, 2016, 127, 1449-1458.	1.4	99
24	Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer Journal, 2016, 6, e385-e385.	6.2	96
25	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	3.5	93
26	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Advances, 2018, 2, 370-380.	5.2	90
27	WHO-defined â€˜myelodysplastic syndrome with isolated del(5q)â€™ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia, 2010, 24, 1283-1289.	7.2	88
28	Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. British Journal of Haematology, 2014, 165, 273-286.	2.5	86
29	SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia, 2013, 27, 2100-2102.	7.2	85
30	Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population. Hepatology Communications, 2022, 6, 399-410.	4.3	84
31	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. American Journal of Hematology, 2020, 95, 1511-1521.	4.1	83
32	Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside. Mayo Clinic Proceedings, 2018, 93, 904-916.	3.0	81
33	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusionâ€“Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	1.6	80
34	Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1180-1189.	2.4	80
35	Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia, 2011, 25, 266-270.	7.2	78
36	Prognostic irrelevance of ring sideroblast percentage in World Health Organizationâ€“defined myelodysplastic syndromes without excess blasts. Blood, 2012, 119, 5674-5677.	1.4	73

#	Article	IF	Citations
37	Targeted nextâ€generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSSâ€R. American Journal of Hematology, 2017, 92, 1311-1317.	4.1	73
38	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine, 2018, 31, 174-181.	6.1	72
39	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. Journal of Clinical Oncology, 2021, 39, 3328-3339.	1.6	72
40	Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARSâ€T) and the role of nextâ€generation sequencing. American Journal of Hematology, 2016, 91, 492-498.	4.1	70
41	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer Journal, 2017, 7, e584-e584.	6.2	68
42	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	5.2	68
43	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)â€"a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	7.2	68
44	Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer Journal, 2017, 7, e592-e592.	6.2	66
45	The importance ofFLT3mutational analysis in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2273-2286.	1.3	66
46	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia, 2019, 33, 2466-2480.	7.2	66
47	Targeted next generation sequencing and identification of risk factors in <scp>W</scp>orld <scp>H</scp>ealth <scp>O</scp>rganization defined atypical chronic myeloid leukemia. American Journal of Hematology, 2017, 92, 542-548.	4.1	64
48	Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clinical Epigenetics, 2016, 8, 68.	4.1	62
49	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 2019, 3, 508-518.	5.2	62
50	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (<scp>RARS</scp>â€<scp>T</scp>): 2017 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2017, 92, 297-310.	4.1	61
51	DNMT3A mutations are associated with inferior overall and leukemiaâ€free survival in chronic myelomonocytic leukemia. American Journal of Hematology, 2017, 92, 56-61.	4.1	60
52	A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). Frontiers in Immunology, 2019, 10, 777.	4.8	59
53	Radius: A Phase 2 Randomized Trial Investigating Standard of Care Â± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML. Blood, 2018, 132, 662-662.	1.4	59
54	Clinical Heterogeneity of the VEXAS Syndrome. Mayo Clinic Proceedings, 2021, 96, 2653-2659.	3.0	58

#	Article	IF	Citations
55	Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Research, 2014, 49, 100.	1.3	56
56	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	4.6	56
57	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget, 2017, 8, 27145-27154.	1.8	55
58	Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2016, 91, 631-642.	4.1	53
59	Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clinic Proceedings, 2017, 92, 1617-1624.	3.0	53
60	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. American Journal of Hematology, 2019, 94, 767-779.	4.1	51
61	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	5.2	51
62	Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. American Journal of Hematology, 2015, 90, 411-416.	4.1	50
63	Mutations and prognosis in myelodysplastic syndromes: karyotypeâ€adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. American Journal of Hematology, 2018, 93, 691-697.	4.1	50
64	Age and platelet count are IPSSâ€independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. European Journal of Haematology, 2010, 84, 105-108.	2.2	49
65	Therapy relatedâ€chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. American Journal of Hematology, 2018, 93, 65-73.	4.1	49
66	Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1488-1493.	1.3	47
67	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	4.1	46
68	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature Communications, 2021, 12, 2901.	12.8	44
69	Spectrum of myeloid neoplasms and immune deficiency associated with germline <scp>GATA</scp>2 mutations. Cancer Medicine, 2015, 4, 490-499.	2.8	43
70	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood, 2020, 136, 1477-1486.	1.4	43
71	Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer Journal, 2016, 6, e472-e472.	6.2	42
72	Refractory anemia with ring sideroblasts and <scp>RARS</scp> with thrombocytosis. American Journal of Hematology, 2015, 90, 549-559.	4.1	41

#	Article	IF	Citations
73	EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer Journal, 2018, 8, 12.	6.2	41
74	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2019, 54, 204-211.	2.4	41
75	Vancomycinâ€resistant <scp>E</scp>nterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transplant Infectious Disease, 2016, 18, 913-920.	1.7	40
76	Monocytosis in polycythemia vera: Clinical and molecular correlates. American Journal of Hematology, 2017, 92, 640-645.	4.1	40
77	Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology, 2018, 93, 649-654.	4.1	40
78	Chromosome 8p11.2 translocations: Prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. American Journal of Hematology, 2010, 85, 238-242.	4.1	39
79	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer Journal, 2015, 5, e270-e270.	6.2	39
80	Genotypeâ€“phenotype correlation of hereditary erythrocytosis mutations, a single center experience. American Journal of Hematology, 2018, 93, 1029-1041.	4.1	38
81	Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: A retrospective study. Thrombosis Research, 2015, 135, 109-113.	1.7	36
82	Phase 1 study of lenzilumab, a recombinant antiâ€“human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood, 2020, 136, 909-913.	1.4	36
83	Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: â€œ2019 Update on Diagnosis, Riskâ€stratification, and Managementâ€. American Journal of Hematology, 2019, 94, 475-488.	4.1	35
84	Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2022, 97, 352-372.	4.1	35
85	Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. American Journal of Hematology, 2017, 92, E614-E618.	4.1	34
86	Aberrant expression of CD123 (interleukin-3 receptor-Î±) on neoplastic mast cells. Leukemia, 2015, 29, 1605-1608.	7.2	33
87	A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood, 2016, 128, 1913-1917.	1.4	33
88	Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. British Journal of Haematology, 2018, 183, 835-838.	2.5	32
89	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 2020, 34, 656-661.	7.2	32
90	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer Journal, 2015, 5, e315-e315.	6.2	31

#	Article	IF	Citations
91	Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1478-1484.	2.0	31
92	Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. American Journal of Hematology, 2013, 88, 690-693.	4.1	30
93	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer Journal, 2016, 6, e405-e405.	6.2	30
94	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leukemia and Lymphoma, 2017, 58, 872-881.	1.3	29
95	Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Hematology American Society of Hematology Education Program, 2020, 2020, 450-459.	2.5	29
96	Myelodysplastic syndromes with ring sideroblasts (<scp>MDSâ€RS</scp>) and <scp>MDS</scp>/myeloproliferative neoplasm with <scp>RS</scp> and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) â€“ â€œ<scp>2021</scp> update on diagnosis, riskâ€stratification, and managementâ€. American Journal of Hematology, 2021, 96, 379-394.	4.1	29
97	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	6.2	28
98	Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms. Blood Advances, 2022, 6, 528-532.	5.2	27
99	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, 1431-1439.	2.0	26
100	Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia, 2018, 32, 2512-2518.	7.2	26
101	A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. Leukemia, 2018, 32, 1850-1856.	7.2	25
102	Mutations and karyotype predict treatment response in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1420-1426.	4.1	25
103	Hereditary Predisposition to Hematopoietic Neoplasms. Mayo Clinic Proceedings, 2020, 95, 1482-1498.	3.0	25
104	Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 2020, 34, 2519-2524.	7.2	25
105	Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation. Biology of Blood and Marrow Transplantation, 2016, 22, 1710-1716.	2.0	24
106	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Laboratory Investigation, 2017, 97, 494-497.	3.7	24
107	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. Blood Cancer Journal, 2018, 8, 82.	6.2	24
108	Cytogenetic abnormalities in systemic mastocytosis: WHO subcategoryâ€specific incidence and prognostic impact among 348 informative cases. American Journal of Hematology, 2018, 93, 1461-1466.	4.1	24

#	Article	IF	Citations
109	Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood, 2022, 139, 1066-1079.	1.4	24
110	Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. European Journal of Haematology, 2010, 84, 518-524.	2.2	23
111	Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. American Journal of Hematology, 2011, 86, 393-398.	4.1	23
112	Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia, 2016, 30, 2273-2275.	7.2	23
113	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer Journal, 2016, 6, e414-e414.	6.2	23
114	Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clinic Proceedings, 2016, 91, 259-272.	3.0	23
115	Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization. American Journal of Clinical Pathology, 2016, 146, 86-94.	0.7	22
116	Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Hematology American Society of Hematology Education Program, 2020, 2020, 460-464.	2.5	22
117	Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?. Seminars in Hematology, 2021, 58, 226-229.	3.4	22
118	Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. European Journal of Haematology, 2016, 97, 313-320.	2.2	21
119	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer Journal, 2017, 7, e550-e550.	6.2	21
120	Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. Biology of Blood and Marrow Transplantation, 2018, 24, 1906-1913.	2.0	21
121	Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clinic Proceedings, 2019, 94, 1753-1768.	3.0	21
122	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer Journal, 2020, 10, 121.	6.2	21
123	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 546-549.	0.4	20
124	Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1â€PDGFRA mutation. American Journal of Hematology, 2016, 91, E10-1.	4.1	20
125	Targeted next generation sequencing of <scp>PDGFRB</scp> rearranged myeloid neoplasms with monocytosis. American Journal of Hematology, 2016, 91, E12-4.	4.1	20
126	Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes. Mayo Clinic Proceedings, 2018, 93, 834-839.	3.0	20

#	Article	IF	Citations
127	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clinic Proceedings, 2018, 93, 1363-1374.	3.0	20
128	Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 453-453.	1.4	20
129	Clinical and laboratory characteristics in congenitalANKRD26mutation-associated thrombocytopenia: A detailed phenotypic study of a family. Platelets, 2016, 27, 712-715.	2.3	19
130	Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biology of Blood and Marrow Transplantation, 2016, 22, 579-583.	2.0	19
131	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2018, 8, 18.	6.2	19
132	Characteristics of late transplantâ€assocíated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2020, 95, 1170-1179.	4.1	19
133	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	5.2	19
134	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	4.1	19
135	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Blood, 2019, 134, 558-558.	1.4	19
136	Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2248-2248.	1.4	19
137	Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNâ€RSâ€T). American Journal of Hematology, 2018, 93, E27-E30.	4.1	18
138	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. Leukemia Research, 2018, 71, 60-62.	0.8	18
139	Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica, 2019, 104, e236-e239.	3.5	18
140	Association between anemia and hematological indices with mortality among cardiac intensive care unit patients. Clinical Research in Cardiology, 2020, 109, 616-627.	3.3	18
141	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Modern Pathology, 2020, 33, 334-343.	5.5	18
142	Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia, 2021, 35, 3299-3303.	7.2	18
143	Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms. Blood, 2014, 124, 5577-5577.	1.4	18
144	A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. Blood, 2016, 128, 100-100.	1.4	18

#	Article	IF	Citations
145	Temozolomide induced bone marrow Suppressionâ€“A single institution outcome analysis and review of the literature. American Journal of Hematology, 2015, 90, E183-4.	4.1	17
146	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. American Journal of Hematology, 2017, 92, 866-871.	4.1	17
147	Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. Blood Cancer Journal, 2019, 9, 65.	6.2	17
148	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	1.3	17
149	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2022, 97, E62.	4.1	17
150	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nature Communications, 2022, 13, 1434.	12.8	17
151	Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2015, 90, 1623-1638.	3.0	16
152	WILD syndrome is GATA2 deficiency: A novel deletion in the GATA2 gene. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1149-1152.e1.	3.8	16
153	Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). Blood Cancer Journal, 2017, 7, 658.	6.2	16
154	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Advances, 2020, 4, 5425-5430.	5.2	16
155	Acute leukemia in pregnancy: a single institution experience with 23 patients. Leukemia and Lymphoma, 2017, 58, 1052-1060.	1.3	15
156	U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. American Journal of Hematology, 2018, 93, E146-E148.	4.1	15
157	Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. Blood, 2011, 118, 3803-3803.	1.4	15
158	Clonal hematopoiesis: Molecular and clinical implications. Leukemia Research, 2022, 113, 106787.	0.8	15
159	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood Cancer Journal, 2013, 3, e122-e122.	6.2	14
160	Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transplant Infectious Disease, 2016, 18, 216-226.	1.7	14
161	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLAâ€matched peripheral blood hematopoietic cell transplantation after reducedâ€intensity conditioning. Transfusion, 2016, 56, 518-527.	1.6	14
162	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer Journal, 2020, 10, 36.	6.2	14

#	Article	IF	Citations
163	Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies. American Journal of Hematology, 2020, 95, E114-E117.	4.1	14
164	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. British Journal of Haematology, 2022, 196, 975-983.	2.5	14
165	Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. Current Hematologic Malignancy Reports, 2022, 17, 61-68.	2.3	14
166	Molecular diagnosis of myeloproliferative neoplasms. Expert Review of Molecular Diagnostics, 2009, 9, 481-492.	3.1	13
167	Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leukemia Research Reports, 2016, 5, 7-10.	0.4	13
168	Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leukemia and Lymphoma, 2018, 59, 2998-3001.	1.3	13
169	Concomitant Erdheimâ€Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. British Journal of Haematology, 2019, 187, e51-e54.	2.5	13
170	Juvenile myelomonocytic leukemia â€“ A bona fide RASopathy syndrome. Best Practice and Research in Clinical Haematology, 2020, 33, 101171.	1.7	13
171	ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility. Blood, 2020, 136, 27-28.	1.4	13
172	Realâ€world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. American Journal of Hematology, 2022, 97, .	4.1	13
173	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood, 2022, 140, 1408-1418.	1.4	13
174	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leukemia and Lymphoma, 2017, 58, 2588-2597.	1.3	12
175	Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 32.	6.2	12
176	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clinic Proceedings, 2019, 94, 1467-1474.	3.0	12
177	Autoimmunity, Clonal Hematopoiesis, and Myeloid Neoplasms. Rheumatic Disease Clinics of North America, 2020, 46, 429-444.	1.9	12
178	Bone marrow findings in Erdheim-Chester disease: increased prevalence of chronic myeloid neoplasms. Haematologica, 2020, 105, e84-e86.	3.5	12
179	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving postâ€autologous stem cell transplantation lenalidomide maintenance therapy. American Journal of Hematology, 2021, 96, E157-E162.	4.1	12
180	Coagulation abnormalities and haemostatic surgical outcomes in 142 patients with Noonan syndrome. Haemophilia, 2017, 23, e237-e240.	2.1	12

#	Article	IF	Citations
181	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1821-1821.	1.4	12
182	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. Blood, 2020, 136, 19-21.	1.4	12
183	CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia, 2014, 28, 1370-1371.	7.2	11
184	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AÂSingle-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 699-704.	0.4	11
185	Clinical outcomes of <scp>HLA</scp>â€<scp>DPB</scp>1 mismatches in 10/10 <scp>HLA</scp>â€matched unrelated donorâ€recipient pairs undergoing allogeneic stem cell transplant. European Journal of Haematology, 2017, 99, 275-282.	2.2	11
186	Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. Advances in Cell and Gene Therapy, 2019, 2, e48.	0.9	11
187	Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. American Journal of Clinical Pathology, 2020, 153, 656-663.	0.7	11
188	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	1.2	11
189	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
190	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 63.	6.2	11
191	Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation. Chest, 2021, 159, 2325-2333.	0.8	11
192	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood, 2013, 122, 662-662.	1.4	11
193	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. Blood Advances, 2022, , .	5.2	11
194	Clinical characteristics and platelet phenotype in a family withRUNX1mutated thrombocytopenia. Leukemia and Lymphoma, 2017, 58, 1963-1967.	1.3	10
195	Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirtyâ€nine patients. American Journal of Hematology, 2018, 93, 1347-1357.	4.1	10
196	Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 2019, 21, 101.	4.0	10
197	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <scp>SARSâ€CoV</scp>â€2 pandemic. American Journal of Hematology, 2020, 95, E203-E208.	4.1	10
198	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leukemia and Lymphoma, 2021, 62, 2568-2586.	1.3	10

#	Article	IF	Citations
199	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. American Journal of Clinical Pathology, 2021, 156, 679-690.	0.7	10
200	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 2739-2751.	7.2	10
201	Outcomes of venetoclaxâ€based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E433-E436.	4.1	10
202	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40.	1.4	10
203	ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. Blood, 2013, 122, 1510-1510.	1.4	10
204	Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American Journal of Hematology, 2022, 97, .	4.1	10
205	Midostaurin for the treatment of acute myeloid leukemia. Future Oncology, 2017, 13, 1853-1871.	2.4	9
206	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. Leukemia and Lymphoma, 2018, 59, 2737-2739.	1.3	9
207	Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. American Journal of Hematology, 2019, 94, E231-E234.	4.1	9
208	A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. Blood Cancer Journal, 2019, 9, 11.	6.2	9
209	Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. Leukemia and Lymphoma, 2019, 60, 1337-1339.	1.3	9
210	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia and Lymphoma, 2019, 60, 990-999.	1.3	9
211	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. British Journal of Haematology, 2020, 190, e316-e320.	2.5	9
212	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. Journal of Biological Chemistry, 2020, 295, 2698-2712.	3.4	9
213	Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. JAMA Dermatology, 2020, 156, 631.	4.1	9
214	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood, 2021, 137, 513-523.	1.4	9
215	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416.	2.5	9
216	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	1.4	9

#	Article	IF	Citations
217	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	5.2	9
218	Sustained, complete response to pexidartinib in a patient with <scp>CSF1R</scp>â€mutated Erdheimâ€“Chester disease. American Journal of Hematology, 2022, 97, 293-302.	4.1	9
219	How I diagnose and treat chronic myelomonocytic leukemia. Haematologica, 2022, 107, 1503-1517.	3.5	9
220	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leukemia Research, 2016, 50, 112-115.	0.8	8
221	FGFR1rearranged hematological neoplasms â€“ molecularly defined and clinically heterogeneous. Leukemia and Lymphoma, 2018, 59, 1520-1522.	1.3	8
222	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	6.2	8
223	Response to erythropoiesisâ€stimulating agents in patients with WHOâ€defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPNâ€RSâ€T). British Journal of Haematology, 2020, 189, e104-e108.	2.5	8
224	Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 2021, 35, 644-649.	7.2	8
225	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€“ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	2.7	8
226	Highâ€oxygenâ€affinity hemoglobinopathyâ€associated erythrocytosis: Clinical outcomes and impact of therapy in 41 cases. American Journal of Hematology, 2021, 96, 1647-1654.	4.1	8
227	Clinical and Molecular Profile Of Hereditary Antithrombin (AT) Deficiency: A Single Institution Cohort. Blood, 2013, 122, 2369-2369.	1.4	8
228	Vacuoles, <scp>E1</scp> enzyme, Xâ€linked, autoinflammatory, somatic (<scp>VEXAS</scp>) syndrome: a presentation of two cases with dermatologic findings. International Journal of Dermatology, 2023, 62, .	1.0	8
229	Prognostic impact of combined NPM1+/FLT3âˆ’ genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leukemia Research, 2015, 39, 1207-1213.	0.8	7
230	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2016, 57, 1714-1715.	1.3	7
231	The 2016 revised World Health Organization definition of â€˜myelodysplastic syndrome with isolated del(5q)â€™; prognostic implications of single versus double cytogenetic abnormalities. British Journal of Haematology, 2017, 178, 57-60.	2.5	7
232	Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis. Journal of Clinical Apheresis, 2019, 34, 666-671.	1.3	7
233	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. American Journal of Hematology, 2019, 94, 5-9.	4.1	7
234	Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. Current Opinion in Hematology, 2020, 27, 2-10.	2.5	7

#	Article	IF	Citations
235	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 764-767.	1.3	7
236	Acute myeloid leukemia after age 70â€‰years: A retrospective comparison of survival following treatment with intensive versus <scp>HMA</scp>â€‰Â±â€‰venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111.	4.1	7
237	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
238	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	4.1	7
239	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20â€‰mg twice daily or higher: A realâ€world experience. British Journal of Haematology, 2022, 198, .	2.5	7
240	A dynamic 3â€factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology, 2022, 97, 1127-1134.	4.1	7
241	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	6.2	7
242	Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia. Case Reports in Hematology, 2013, 2013, 1-4.	0.4	6
243	Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e39-e41.	0.4	6
244	Angiosarcoma of the Prostate Gland following Brachytherapy for Prostatic Adenocarcinoma. Current Urology, 2015, 8, 109-112.	0.6	6
245	Patterns of Care and Survival for Elderly Acute Myeloid Leukemiaâ€"Challenges and Opportunities. Current Hematologic Malignancy Reports, 2017, 12, 290-299.	2.3	6
246	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. Human Immunology, 2018, 79, 532-536.	2.4	6
247	Subacute demyelinating polyradiculoneuropathy complicating Epsteinâ€"Barr virus infection in GATA2 haploinsufficiency. Muscle and Nerve, 2018, 57, 150-156.	2.2	6
248	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	3.0	6
249	QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia. Leukemia and Lymphoma, 2019, 60, 3512-3520.	1.3	6
250	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1232-1239.	2.0	6
251	A populationâ€based study of chronic eosinophilic <scp>leukemiaâ€not</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257.	4.1	6
252	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	6.2	6

#	Article	IF	Citations
253	Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia, 2021, 35, 3329-3333.	7.2	6
254	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology, 2021, 96, E327-E330.	4.1	6
255	Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. Blood Cancer Journal, 2021, 11, 170.	6.2	6
256	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>) but not in <scp>MDS</scp>/<scp>MPNâ€RSâ€T</scp>. American Journal of Hematology, 2022, 97, .	4.1	6
257	Grey platelet syndrome misdiagnosed as <scp>ITP</scp>. British Journal of Haematology, 2016, 173, 662-662.	2.5	5
258	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of Hematology, 2019, 98, 331-337.	1.8	5
259	CDK2-Mediated Upregulation of TNFÎ± as a Mechanism of Selective Cytotoxicity in Acute Leukemia. Cancer Research, 2021, 81, 2666-2678.	0.9	5
260	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	6.2	5
261	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. Journal of Clinical Medicine, 2021, 10, 2264.	2.4	5
262	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320.	1.4	5
263	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. Blood, 2021, 138, 2158-2158.	1.4	5
264	Targeting ineffective hematopoiesis in myelodysplastic syndromes. American Journal of Hematology, 2022, 97, 171-173.	4.1	5
265	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer Journal, 2022, 12, 7.	6.2	5
266	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26.	6.2	5
267	Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML. Leukemia Research, 2022, 116, 106818.	0.8	5
268	Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Advances, 2022, 6, 5227-5231.	5.2	5
269	MYST3/CREBBPRearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer. Case Reports in Oncological Medicine, 2014, 2014, 1-3.	0.3	4
270	von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. British Journal of Haematology, 2017, 176, 994-997.	2.5	4

#	Article	IF	Citations
271	Influenza infection in neutropenic adults. Infectious Diseases, 2017, 49, 141-146.	2.8	4
272	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget, 2017, 8, 94569-94579.	1.8	4
273	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. British Journal of Haematology, 2018, 182, 141-145.	2.5	4
274	Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 341-347.	2.3	4
275	Phenotypic heterogeneity associated with germline GATA2 haploinsufficiency: a comprehensive kindred study. Leukemia and Lymphoma, 2019, 60, 3282-3286.	1.3	4
276	Differential expression of interferonâ€induced genes and other tissueâ€based biomarkers in acute graftâ€versusâ€host disease vs. lupus erythematosus in skin. Clinical and Experimental Dermatology, 2019, 44, e81-e88.	1.3	4
277	Clinical utility of fluorescence in situ hybridizationâ€based diagnosis of BCRâ€ABL1 like (<scp>P</scp>hiladelphia chromosome like) <scp>B</scp>â€cute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	4.1	4
278	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal, 2021, 11, 156.	6.2	4
279	A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 4234-4234.	1.4	4
280	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	1.4	4
281	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 110-110.	1.4	4
282	Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms. Blood, 2019, 134, 1697-1697.	1.4	4
283	Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience. Haematologica, 2022, 107, 1201-1204.	3.5	4
284	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with â€œ7+3â€. Blood Cancer Journal, 2022, 12, 55.	6.2	4
285	Myeloid malignancy presenting with a platelet storage pool disorder. Leukemia and Lymphoma, 2013, 54, 1800-1801.	1.3	3
286	Chronic myelomonocytic leukemia: molecularly contaminated, but not defined. Leukemia and Lymphoma, 2016, 57, 1751-1752.	1.3	3
287	FLT3 Mutation Testing in Acute Myeloid Leukemia. JAMA Oncology, 2017, 3, 991.	7.1	3
288	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. American Journal of Hematology, 2017, 92, E626-E627.	4.1	3

#	Article	IF	Citations
289	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3â€•ITD mutational status. American Journal of Hematology, 2018, 93, E401-E404.	4.1	3
290	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leukemia and Lymphoma, 2019, 60, 2483-2487.	1.3	3
291	Treatment of Acquired Sideroblastic Anemias. Hematology/Oncology Clinics of North America, 2020, 34, 401-420.	2.2	3
292	Phenotypic correlates and prognostic outcomes of <scp>TET2</scp> mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American Journal of Hematology, 2020, 95, E86-E89.	4.1	3
293	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. Bone Marrow Transplantation, 2021, 56, 960-962.	2.4	3
294	Remarkable stability in clonal hematopoiesis involving leukemiaâ€driver genes in patients without underlying myeloid neoplasms. American Journal of Hematology, 2021, 96, E392-E396.	4.1	3
295	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204.	1.3	3
296	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. Blood, 2018, 132, 961-961.	1.4	3
297	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. Blood, 2018, 132, 1773-1773.	1.4	3
298	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 4581-4581.	1.4	3
299	Real-World â€œmyelodysplastic Syndrome-unclassifiableâ€•and Its Comparison With â€œrefractory Cytopenia With Multi-Lineage dysplasiaâ€•and â€œrefractory anemiaâ€• Blood, 2013, 122, 1574-1574.	1.4	3
300	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. Blood, 2015, 126, 5234-5234.	1.4	3
301	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. Blood, 2015, 126, 55-55.	1.4	3
302	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. Blood, 2016, 128, 2798-2798.	1.4	3
303	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. Blood, 2016, 128, 3604-3604.	1.4	3
304	"Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. Blood, 2016, 128, 1987-1987.	1.4	3
305	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. Blood, 2021, 138, 219-219.	1.4	3
306	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	1.4	3

#	Article	IF	Citations
307	<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica, 2022, 107, 1189-1192.	3.5	3
308	Immunophenotypic and molecular comparison between allogeneic and autologous graftâ€vsâ€host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. Journal of Cutaneous Pathology, 2017, 44, 1087-1091.	1.3	2
309	Preâ€anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. American Journal of Hematology, 2018, 93, E144-E146.	4.1	2
310	Practiceâ€relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. American Journal of Hematology, 2018, 93, E383-E386.	4.1	2
311	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. American Journal of Hematology, 2018, 93, E355-E357.	4.1	2
312	Blast-phase chronic myelomonocytic leukemia: more than just semantics. Leukemia, 2018, 32, 2093-2094.	7.2	2
313	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. Leukemia and Lymphoma, 2019, 60, 821-824.	1.3	2
314	Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. American Journal of Hematology, 2020, 95, E31-E34.	4.1	2
315	Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer Journal, 2020, 10, 120.	6.2	2
316	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. Anticancer Research, 2020, 40, 3883-3888.	1.1	2
317	Transplant Characteristics and Outcomes of Philadelphia (Ph)-like Acute Lymphoblastic Leukemia (ALL). Biology of Blood and Marrow Transplantation, 2020, 26, S114-S115.	2.0	2
318	Novel therapeutic targets for chronic myelomonocytic leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101244.	1.7	2
319	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 328-350.	3.8	2
320	Pregnancy in patients with myelofibrosis: Mayoâ€“Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	2.5	2
321	Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes. Blood, 2019, 134, 4273-4273.	1.4	2
322	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460.	1.4	2
323	Genomics Of Familial Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2013, 122, 2803-2803.	1.4	2
324	Spectrum of Mutations Associated with Hereditary Erythrocytosis. Blood, 2015, 126, 2140-2140.	1.4	2

#	Article	IF	Citations
325	Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia. Blood, 2015, 126, 2563-2563.	1.4	2
326	Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing. Blood, 2015, 126, 736-736.	1.4	2
327	ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. Blood, 2015, 126, 2882-2882.	1.4	2
328	Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression. Blood, 2019, 134, 3790-3790.	1.4	2
329	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	1.4	2
330	DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. Blood, 2021, 138, 3693-3693.	1.4	2
331	Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation. Leukemia and Lymphoma, 2022, , 1-9.	1.3	2
332	47-Year-Old Man With Pruritus. Mayo Clinic Proceedings, 2016, 91, 241-245.	3.0	1
333	A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. American Journal of Hematology, 2018, 93, E103-E107.	4.1	1
334	In Replyâ€"Short Telomere Syndromes, Biological Aging, and Hematopoietic Stem Cell Transplantation. Mayo Clinic Proceedings, 2018, 93, 1685-1687.	3.0	1
335	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E398-E401.	4.1	1
336	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. Clinical Genitourinary Cancer, 2018, 16, e1117-e1122.	1.9	1
337	MPN-379: Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S339.	0.4	1
338	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	2.5	1
339	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a â€˜graft versus hostâ€™-like syndrome and poor outcomes. Bone Marrow Transplantation, 2020, 55, 1879-1881.	2.4	1
340	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	1.8	1
341	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. Kidney International Reports, 2021, 6, 1050-1057.	0.8	1
342	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Blood, 2018, 132, 3035-3035.	1.4	1

#	Article	IF	Citations
343	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. Blood, 2019, 134, 4560-4560.	1.4	1
344	Spectrum of Abnormalities and Clonal Transformation in Germline RUNX1 Familial Platelet Disorder and a Comparative Analysis with Somatic RUNX1 Mutations in Myeloid Neoplasms. Blood, 2019, 134, 3003-3003.	1.4	1
345	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2020, 136, 7-8.	1.4	1
346	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. Blood, 2013, 122, 1732-1732.	1.4	1
347	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. Blood, 2013, 122, 2821-2821.	1.4	1
348	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. Blood, 2013, 122, 4049-4049.	1.4	1
349	Early T-Lymphocyte Chimerism Kinetics Is Influenced By Conditioning Regimen in Reduced Intensity Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 1923-1923.	1.4	1
350	Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Blood, 2015, 126, 3210-3210.	1.4	1
351	Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. Blood, 2016, 128, 4343-4343.	1.4	1
352	Feasibility of Allogeneic Hematopoietic Stem Cell Transplant for High Risk FLT3-ITD Mutant Patients with Acute Myeloid Leukemia in CR1- a Real Word Analysis. Blood, 2016, 128, 4694-4694.	1.4	1
353	No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer. Blood, 2011, 118, 4259-4259.	1.4	1
354	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1476-1476.	1.4	1
355	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 3873-3873.	1.4	1
356	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. Blood, 2013, 122, 1334-1334.	1.4	1
357	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. Blood, 2016, 128, 5534-5534.	1.4	1
358	Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1813-1813.	1.4	1
359	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. Blood, 2018, 132, 5440-5440.	1.4	1
360	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). Blood, 2019, 134, 4182-4182.	1.4	1

#	Article	IF	Citations
361	Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a. Blood, 2019, 134, 4220-4220.	1.4	1
362	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. Blood, 2019, 134, 3863-3863.	1.4	1
363	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. Blood, 2021, 138, 3657-3657.	1.4	1
364	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. Blood, 2021, 138, 3368-3368.	1.4	1
365	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
366	Clonal Hematopoiesis of Indeterminate Potential Is Associated with Increased Age-Independent Morbidity and Mortality in Patients with COVID-19- the Beyond DNA COVID-19 Project. Blood, 2021, 138, 2164-2164.	1.4	1
367	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	1.4	1
368	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer Journal, 2022, 12, 12.	6.2	1
369	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia, 2022, 36, 1693-1696.	7.2	1
370	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	6.2	1
371	Fanconi Anemiaâ€"Protean Manifestations of Defective DNA Repair. Mayo Clinic Proceedings, 2016, 91, 824-825.	3.0	0
372	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. International Journal of Hematology, 2016, 103, 409-415.	1.6	0
373	Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2019-2020.	2.0	0
374	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	3.3	0
375	Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Case Reports in Hematology, 2017, 2017, 1-4.	0.4	0
376	45-Year-Old Man With Abdominal Pain and Splenomegaly. Mayo Clinic Proceedings, 2018, 93, e113-e117.	3.0	0
377	Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia Research, 2019, 87, 106264.	0.8	0
378	Myelodysplastic/myeloproliferative neoplasms â€“ Justified inclusion as unique biological entities. Best Practice and Research in Clinical Haematology, 2020, 33, 101135.	1.7	0

#	Article	IF	Citations
379	Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes â€“ Advances in treatment. Best Practice and Research in Clinical Haematology, 2020, 33, 101130.	1.7	0
380	Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 508-510.	2.4	0
381	Treatment advances for pediatric and adult onset neoplasms with monocytosis. Current Hematologic Malignancy Reports, 2021, 16, 256-266.	2.3	0
382	Isolated Tâ€cell acute lymphoblastic leukemic optic disc infiltration. American Journal of Hematology, 2021, 96, 1717-1718.	4.1	0
383	3q21 deletion affects GATA2 and is associated with myelodysplastic syndrome. British Journal of Haematology, 2022, 196, 1120-1123.	2.5	0
384	Clinical & Molecular Analysis of Patients with Type 2 (Qualitative) Hereditary Antithrombin (AT) Deficiency. Blood, 2010, 116, 4201-4201.	1.4	0
385	Clinicopathological and Cytogenetic Comparison of Patients with Acute T Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood, 2010, 116, 2705-2705.	1.4	0
386	Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. Blood, 2011, 118, 971-971.	1.4	0
387	Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. Blood, 2012, 120, 1711-1711.	1.4	0
388	Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT) have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM). Blood, 2012, 120, 600-600.	1.4	0
389	Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with â‰¥ 1% Ring Sideroblasts.. Blood, 2012, 120, 2803-2803.	1.4	0
390	Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center.. Blood, 2012, 120, 2850-2850.	1.4	0
391	Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. Blood, 2012, 120, 3790-3790.	1.4	0
392	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 423-423.	1.4	0
393	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 1405-1405.	1.4	0
394	Familial Myeloid Neoplasms: Clinical Spectrum and Associated Abnormalities. Blood, 2013, 122, 2794-2794.	1.4	0
395	Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis. Blood, 2013, 122, 5472-5472.	1.4	0
396	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. Blood, 2013, 122, 4048-4048.	1.4	0

#	Article	IF	Citations
397	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. Blood, 2013, 122, 4955-4955.	1.4	0
398	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. Blood, 2013, 122, 2098-2098.	1.4	0
399	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. Blood, 2013, 122, 5226-5226.	1.4	0
400	Voriconazole Exposure and The Risk Of Cutaneous Squamous Cell Carcinoma In Allogeneic Hematopoietic Stem Cell Transplant Patients. Blood, 2013, 122, 916-916.	1.4	0
401	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. Blood, 2013, 122, 3375-3375.	1.4	0
402	Incidence Of Symptomatic Venous Thromboembolism In Patients With Hemophilia Undergoing Joint Replacement Surgery: A Retrospective Study. Blood, 2013, 122, 2348-2348.	1.4	0
403	Extramedullary Leukemia Relapse In Patients With Acute Myeloid Leukemia Allogeneic Stem Cell Transplantation: Risk Factors and Prognosis. Blood, 2013, 122, 2081-2081.	1.4	0
404	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	1.4	0
405	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. Blood, 2015, 126, 3730-3730.	1.4	0
406	Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). Blood, 2015, 126, 4067-4067.	1.4	0
407	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. Blood, 2015, 126, 5260-5260.	1.4	0
408	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. Blood, 2015, 126, 4980-4980.	1.4	0
409	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	1.4	0
410	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. Blood, 2015, 126, 4910-4910.	1.4	0
411	Iron Deficiency Anemia Associated with Extracorporeal Photophoresis: A Retrospective Analysis. Blood, 2015, 126, 951-951.	1.4	0
412	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875.	1.4	0
413	Clinico-Pathological Features and Outcomes in Patients with Congenital Sideroblastic Anemias. Blood, 2015, 126, 3355-3355.	1.4	0
414	Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2015, 126, 2864-2864.	1.4	0

#	Article	IF	Citations
415	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2015, 126, 1913-1913.	1.4	0
416	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. Blood, 2015, 126, 3747-3747.	1.4	0
417	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	1.4	0
418	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. Blood, 2015, 126, 5254-5254.	1.4	0
419	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	1.4	0
420	Incidence and Outcomes of Neutropenia in Patients with Celiac Disease- a Consecutive Analysis of 1729 Patients. Blood, 2015, 126, 1013-1013.	1.4	0
421	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. Blood, 2016, 128, 1617-1617.	1.4	0
422	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. Blood, 2016, 128, 5541-5541.	1.4	0
423	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. Blood, 2016, 128, 300-300.	1.4	0
424	Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. Blood, 2016, 128, 4259-4259.	1.4	0
425	Day +30 and Day +100 CD33 Chimerisms Predict Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis. Blood, 2016, 128, 4653-4653.	1.4	0
426	Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. Blood, 2016, 128, 1986-1986.	1.4	0
427	DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1988-1988.	1.4	0
428	Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 4593-4593.	1.4	0
429	Coagulation Abnormalities and Hemostatic Surgical Outcomes in 142 Patients with Noonan Syndrome. Blood, 2016, 128, 1417-1417.	1.4	0
430	The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. Blood, 2016, 128, 5542-5542.	1.4	0
431	Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 1989-1989.	1.4	0
432	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making: A Qualitative Patient-Oriented Survey Study. Blood, 2016, 128, 3588-3588.	1.4	0

#	Article	IF	Citations
433	Safety and Efficacy of Fecal Microbiota Transplantation for Recurrent Clostridium Infection in Patients with Hematologic Malignancies. Blood, 2016, 128, 3599-3599.	1.4	0
434	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. Blood, 2018, 132, 1443-1443.	1.4	0
435	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	1.4	0
436	Histopathologic Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation: Clinical Findings, Radiologic Features, Treatments and Outcomes. Blood, 2018, 132, 2113-2113.	1.4	0
437	Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR. Blood, 2018, 132, 3456-3456.	1.4	0
438	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
439	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	1.4	0
440	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. Blood, 2018, 132, 4287-4287.	1.4	0
441	Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. Blood, 2018, 132, 582-582.	1.4	0
442	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 4344-4344.	1.4	0
443	Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. Blood, 2018, 132, 3050-3050.	1.4	0
444	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. Blood, 2018, 132, 3100-3100.	1.4	0
445	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. Blood, 2018, 132, 2689-2689.	1.4	0
446	A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. Blood, 2018, 132, 1771-1771.	1.4	0
447	Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 4232-4232.	1.4	0
448	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. Blood, 2019, 134, 3005-3005.	1.4	0
449	Epigenomic Determinants of Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2987-2987.	1.4	0
450	Clinical Utility of Telomere Length-Directed Genomic Assessment in Patients with Short Telomere Syndromes. Blood, 2019, 134, 1222-1222.	1.4	0

#	Article	IF	Citations
451	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). Blood, 2019, 134, 5441-5441.	1.4	0
452	Risks and Benefits of Bronchoscopy during the First 100 Days Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 4500-4500.	1.4	0
453	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. Blood, 2019, 134, 5406-5406.	1.4	0
454	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2981-2981.	1.4	0
455	Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes. Blood, 2019, 134, 3300-3300.	1.4	0
456	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. Blood, 2019, 134, 2588-2588.	1.4	0
457	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. Blood, 2019, 134, 1710-1710.	1.4	0
458	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genetics, 2021, 260-261, 1-5.	0.4	0
459	High-Oxygen-Affinity Hemoglobinopathy-Associated Erythrocytosis: Clinical Outcomes and Impact of Therapy in 41 Cases. Blood, 2021, 138, 1492-1492.	1.4	0
460	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNÎ²-NIS). Blood, 2021, 138, 1333-1333.	1.4	0
461	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. Blood, 2021, 138, 36-36.	1.4	0
462	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267.	1.4	0
463	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2592-2592.	1.4	0
464	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 3684-3684.	1.4	0
465	Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 1470-1470.	1.4	0
466	A novel Iowaâ€“Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal, 2021, 11, 183.	6.2	0
467	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). Blood, 2021, 138, 1096-1096.	1.4	0
468	Histopathologic Characterization of Vexas Syndrome. Blood, 2021, 138, 4656-4656.	1.4	0

#	Article	IF	Citations
469	Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia. Blood, 2020, 136, 31-32.	1.4	0
470	Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model. Blood, 2020, 136, 10-11.	1.4	0
471	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	1.4	0
472	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. Blood, 2020, 136, 17-18.	1.4	0
473	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	1.4	0
474	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. Blood, 2020, 136, 43-44.	1.4	0
475	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	1.4	0
476	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	1.4	0
477	Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis. Blood, 2020, 136, 19-20.	1.4	0
478	A Man with Progressive Effort Intolerance and Splenomegaly. , 0, , 393-399.		0
479	Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk. Current Hematologic Malignancy Reports, 0, , .	2.3	0
480	Characteristics and prognosis of mutated STAG2 myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19014-e19014.	1.6	0
481	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.. Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	1.6	0
482	Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19010-e19010.	1.6	0